Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,963 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Open enrollment, early-phase tilt
Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.
- 423
- recruiting participants now
- 34%
- of trials open to enrollment
- 120
- in Phase 3-4 (later-stage)
- 98
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 16 of 26
Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities
M.D. Anderson Cancer Center
NCT00453661
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
NSABP Foundation
NCT00002707
Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care
Dartmouth-Hitchcock Medical Center
NCT00477646
Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women
Case Comprehensive Cancer Center
NCT00445445
Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer
University of Colorado, Denver
NCT00830635
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
NSABP Foundation
NCT00016432
Docetaxel in Node Positive Adjuvant Breast Cancer
Sanofi
NCT00688740
Cancer Screening and Prevention Program for High Risk Women
NYU Langone Health
NCT00849199
Implementing Systematic Distress Screening in Breast Cancer
Kaiser Permanente
NCT02941614
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
Evaluation of Mailers Promoting Mammogram Screening
Geisinger Clinic
NCT04555902
Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives
University of Michigan
NCT01612338
Patient Navigator Project
H. Lee Moffitt Cancer Center and Research Institute
NCT00375024
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
GBG Forschungs
NCT01864746
Breast Cancer Risk Reduction: A Patient Doctor Intervention
University of California, San Francisco
NCT01830933
Acquisition of Breast Mammography Images
Fujifilm Medical Systems USA
NCT02156258
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
R-Pharm
NCT00082433
Evaluation of a 3-D Tomosynthesis Mammography System Used in Conjunction With Conventional 2-D Digital Mammography
Hologic
NCT00754598
Scripps Polster Breast Care Center Investigational GeneBank
Scripps Translational Science Institute
NCT00945464
Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00002762
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
Vanderbilt University Medical Center
NCT05051631
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
Stanford University
NCT03245788
Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
American College of Radiology Imaging Network
NCT00058058
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
Wake Forest University Health Sciences
NCT01407770
Outcomes of a Deep Inferior Epigastric Perforator Flap Program
Beth Israel Deaconess Medical Center
NCT00543907
Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.
M.D. Anderson Cancer Center
NCT00837499
International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study
AstraZeneca
NCT03078036
Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
EirGenix
NCT03433313
Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging
Siemens Medical Solutions USA - CSG
NCT01373671
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00881361
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Eastern Cooperative Oncology Group
NCT00028990
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis Pharmaceuticals
NCT00667251
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00003855
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
Hoffmann-La Roche
NCT01419197
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Memorial Sloan Kettering Cancer Center
NCT00581750
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
Gilead Sciences
NCT02574455
Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening
Michigan State University
NCT01910350
Expanded Breast Cancer Registry and Tissue Repository
New Mexico Cancer Research Alliance
NCT00322894
Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors
Jonsson Comprehensive Cancer Center
NCT01627366
Adj TC + Herceptin Early Stage Breast Cancer
US Oncology Research
NCT00493649
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Puma Biotechnology
NCT00915018
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Alliance for Clinical Trials in Oncology
NCT01376349
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Hoffmann-La Roche
NCT03726879
Reflexology: An Intervention for Advanced Breast Cancer
Michigan State University
NCT01577420
Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Alliance for Clinical Trials in Oncology
NCT00022087
Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost
NYU Langone Health
NCT01591811
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
Novartis Pharmaceuticals
NCT01572727
Investigation of Novel Surgical Imaging for Tumor Excision
Lumicell
NCT03686215
Cone Beam Computed Tomography for Breast Imaging
Koning Corporation
NCT01107860
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
Bristol-Myers Squibb
NCT00455533
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Breast Cancer right now
423 recruiting of 1,251 indexed (34% open).
Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Breast Cancer?
PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Breast Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.